{Reference Type}: Journal Article
{Title}: Water-filtered infrared A radiation hyperthermia combined with immunotherapy for advanced gastrointestinal tumours.
{Author}: Liu P;Wu J;Chen L;Wu Z;Wu Y;Zhang G;Yu B;Zhang B;Wei N;Shi J;Zhang C;Lei L;Yu S;Lai J;Guo Z;Zheng Y;Jing Z;Jiang H;Wang T;Zhou J;Wu Y;Sun C;Shen J;Zhang J;Wu Z;
{Journal}: Cancer Med
{Volume}: 13
{Issue}: 14
{Year}: 2024 Jul
{Factor}: 4.711
{DOI}: 10.1002/cam4.70024
{Abstract}: This study pioneered the use of WIRA whole-body infrared hyperthermia combined with ICI therapy to treat GIT and verified the feasibility and safety of HIT. The final results showed a DCR of 55.6%, with a median PFS of 53.5 days, median OS of 134 days, and an irAE incidence of 22.2%. Therefore, we believe that HIT can exert multiple synergistic sensitisation effects, thereby providing clinical benefits to patients with advanced GITs, increasing overall safety, and improving patients' QOL.<BR><B>BACKGROUND: </B>This study aimed to validate the effectiveness, safety and feasibility of water‐filtered infrared A radiation (WIRA) whole‐body hyperthermia combined with immune checkpoint inhibitor (ICI) therapy (HIT) and evaluate the real‐world clinical application prospects.<BR><B>METHODS: </B>This open‐label single‐arm phase 2 clinical trial (NCT06022692) aimed to enrol advanced gastrointestinal tumour (GIT) patients with the MSS/pMMR phenotype. The patients were treated with whole‐body hyperthermia on Days 1 and 8 of each HIT cycle along with administration of tislelizumab on Day 2.<BR><B>RESULTS: </B>Between 1 June 2020 and 31 May 2022, 18 patients were enrolled in the study, including those with gastric cancer (n = 6), colon cancer (n = 7), rectal cancer (n = 3) and appendiceal cancer (n = 2). As of 19 May 2023, 17 of the 18 patients had died, including 14 deaths caused by tumour progression and three deaths caused by diseases other than cancer, while one patient was still undergoing follow‐up. In terms of efficacy, the median DCR was 55.6%, while the median PFS and OS were 53.5 days and 134 days, respectively. Four patients (22.2%) experienced immune‐related adverse events, and none of the patients reported grade 3 or higher irAEs. Hyperthermia was followed by an increase in the number of tumour immune‐activated cells.<BR><B>CONCLUSIONS: </B>HIT can provide survival benefits in patients with GITs by activating antitumour immune function and shows good safety and feasibility.